This once-faltering cancer startup just raised $117M. Here’s how it plans to spend it.

When Jan Skvarka joined Cambridge’s Trillium Therapeutics as CEO in September 2019, the company had a paltry market cap of $27 million and had been stuck in a drug development rut. Months later, the company may be bouncing back.